3 checks for Dubai cancer patients after Abu Dhabi Biobank’s Cleveland Clinic deal

For cancer patients in Dubai, the 13 October 2026 partnership between Abu Dhabi Biobank and Cleveland Clinic Abu Dhabi changes what to ask about research access, second opinions and insurance approval, rather than where treatment must start.

The highest-stakes reader is the patient choosing care with a family, an oncologist and an insurer. Dubai care remains regulated by the Dubai Health Authority (DHA). Abu Dhabi care falls under the Department of Health – Abu Dhabi (DoH). Cancer services in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain sit under the Ministry of Health and Prevention (MOHAP). That regulator split matters when a Dubai patient wants to move records, seek a referral or ask an insurer to approve treatment outside Dubai.

What the biobank can change for patients

The partnership does one specific thing first. Patients at Cleveland Clinic Abu Dhabi’s Fatima bint Mubarak Center may voluntarily contribute blood and tumour tissue collected during routine visits, with informed consent, for secure storage and research at Abu Dhabi Biobank. The official announcement says the pilot includes somatic sequencing of tumour tissue for all participants who volunteer.

That is useful because somatic sequencing looks at changes in tumour cells. It can support research into why a tumour grows, resists treatment or responds to a therapy. It does not mean every Dubai patient now has direct access to a new drug, a trial place or a free genomic test. Patients should ask whether any sequencing result is returned to their treating doctor, whether it can affect the current treatment plan, and whether the consent form permits future use of samples.

“The project will also help provide research samples from people in the region, strengthening their representation in cancer research on a broader scale.”
Dr Stephen R. Grobmyer, Surgical Oncologist and Institute Chief, Cancer Institute at Cleveland Clinic Abu Dhabi

Abu Dhabi Biobank was inaugurated on 3 April 2026 by DoH and M42. The official statement says its Masdar City infrastructure can store 5 million pan-human samples linked to health data. For patients, the practical question is governance. Ask who can access the sample, whether data is de-identified, how long it is stored, and how consent can be withdrawn.

What a Dubai patient should check first

A Dubai patient should start with the treating oncologist and the insurer before booking an Abu Dhabi consultation. The DHA Basma Programme supports eligible patients with cancer through screening, early detection and treatment at DHA-accredited centres. DHA’s programme material names breast, colorectal and cervical cancer as covered cancer areas. Eligibility, provider route and approval timing should be checked through the insurer and treating provider.

• Referral route: ask whether your Dubai oncologist will issue a referral letter, pathology report, imaging files and treatment summary for Abu Dhabi review.
• Insurance route: ask whether the Abu Dhabi provider is in network and whether pre-authorisation is needed for consultation, imaging, surgery, chemotherapy, radiotherapy or molecular testing.
• Research route: ask whether research consent is separate from treatment consent and whether declining sample donation affects care. It should not.
• Cost route: ask for a written estimate before self-pay care. Cleveland Clinic Abu Dhabi says financial counsellors can provide estimated costs for patients without insurance or with non-partner coverage.

One public Dubai price point is available. A DHA oncology services document lists a AED 255 self-pay consultation for haematology-oncology services, with non-UAE nationals covered by insurance where applicable. Private tertiary oncology prices vary by provider, tumour type, drug regimen, imaging, day-care use and insurer network. If a provider cannot quote a full pathway, ask for a staged estimate for consultation, pathology review, PET-CT or MRI, treatment cycle and follow-up.

When Abu Dhabi may be worth the trip

Abu Dhabi becomes relevant when the question is complex disease, a second opinion, a trial discussion or access to technology that is unavailable in the patient’s current pathway. DoH recently designated Cleveland Clinic Abu Dhabi as an Oncology Centre of Excellence for Breast Cancer. The Abu Dhabi Media Office also says the hospital is set to establish the Middle East’s first heavy ion therapy facility, which would be the only centre of its kind within a five-hour flight radius of the UAE.

That does not reduce the importance of local care in Dubai. Cancer treatment is logistically heavy. Chemotherapy, radiation fractions, blood tests and side-effect management can require repeated visits over weeks or months. A patient living in Dubai should balance clinical benefit against travel time, emergency access and the ability of Dubai and Abu Dhabi teams to share records.

The next step is simple. Dubai patients should ask their DHA-licensed oncologist whether the Abu Dhabi research programme is relevant to their tumour type, then confirm coverage with their insurer before transferring appointments. Patients in Abu Dhabi should check DoH-licensed providers and Daman or Thiqa eligibility where relevant. Patients in the northern emirates should confirm MOHAP-licensed oncology options and referral rules. For a licensed provider search across the country, use the UAE Open Healthcare Directory for oncology providers.